Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates

Journal of Clinical Epidemiology

Volumn 64, Issue 12, 2011, Pages 1412-1417

  Gulati, Roman ^a   Mariotto, Angela B ^b   Chen, Shu ^a   Gore, John L ^c   Etzioni, Ruth ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Cost benefit analysis; Mass screening; Prostate specific antigen; Prostatic neoplasms; Simulation modeling; Treatment efficacy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; CANCER MORTALITY; CANCER SCREENING; CAUSE OF DEATH; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SPECIFIC SURVIVAL; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MATHEMATICAL MODEL; PRIORITY JOURNAL; PROSTATE CANCER; RISK BENEFIT ANALYSIS; SIMULATION; SURVIVAL;

AGED; EARLY DETECTION OF CANCER; EUROPE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MODELS, STATISTICAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; WASHINGTON;

EID: 80055019354     PISSN: 08954356     EISSN: 18785921     Source Type: Journal    
DOI: 10.1016/j.jclinepi.2011.06.011     Document Type: Article

References (27)

1. R. Etzioni, R. Cha, E.J. Feuer, and O. Davidov Asymptomatic incidence and duration of prostate cancer Am J Epidemiol 148 1998 775 785
2. Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence - SEER 9 Regs Limited-Use, Nov 2006 Sub (1973-2005), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2008, based on the November 2007 submission; [cited]. Available at www.seer.cancer.gov. Accessed August 9, 2011.
3. M. McGregor, J.A. Hanley, J.F. Boivin, and R.G. McLean Screening for prostate cancer: estimating the magnitude of overdetection CMAJ 159 1998 1368 1372
4. G. Draisma, R. Boer, S.J. Otto, I.W. van der Cruijsen, R.A. Damhuis, and F.H. Schröder Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer J Natl Cancer Inst 95 2003 868 878
5. R. Etzioni, D.F. Penson, J.M. Legler, D. di Tommaso, R. Boer, and P.H. Gann Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends J Natl Cancer Inst 94 2002 981 990
6. D. Telesca, R. Etzioni, and R. Gulati Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends Biometrics 64 2008 10 19
7. G. Draisma, R. Etzioni, A. Tsodikov, A. Mariotto, E. Wever, and R. Gulati Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context J Natl Cancer Inst 101 2009 374 383
8. A. Tsodikov, A. Szabo, and J. Wegelin A population model of prostate cancer incidence Stat Med 25 2006 2846 2866
9. A. Mariotto, R. Etzioni, M. Krapcho, and E.J. Feuer Reconstructing prostate-specific antigen (PSA) testing patterns among black and white men in the US from Medicare claims and the National Health Interview Survey Cancer 109 2007 1877 1886
10. F.H. Schröder, J. Hugosson, M.J. Roobol, T.L. Tammela, S. Ciatto, and V. Nelen Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 2009 1320 1328
11. P.F. Pinsky, G.L. Andriole, B.S. Kramer, R.B. Hayes, P.C. Prorok, and J.K. Gohagan Prostate biopsy following a positive screen in the Prostate, Lung, Colorectal and Ovarian cancer screening trial J Urol 173 2005 746 750 discussion 50-51
12. G.L. Andriole, E.D. Crawford, R.L. Grubb 3rd, S.S. Buys, D. Chia, and T.R. Church Mortality results from a randomized prostate-cancer screening trial N Engl J Med 360 2009 1310 1319
13. J. Hugosson, S. Carlsson, G. Aus, S. Bergdahl, A. Khatami, and P. Lodding Mortality results from the Goteborg randomised population-based prostate-cancer screening trial Lancet Oncol 11 2010 725 732
14. P.F. Pinsky, A. Blacka, B.S. Kramer, A. Miller, P.C. Prorok, and C. Berg Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial Clin Trials 7 2010 303 311
15. S. Loeb, E.F. Vonesh, E.J. Metter, H.B. Carter, P.H. Gann, and W.J. Catalona What is the true number needed to screen and treat to save a life with prostate-specific antigen testing? J Clin Oncol 29 2011 464 467
16. Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence - SEER 17 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Linked To County Attributes - Total U.S., 1969-2007 Counties [database on the Internet]. Released April 2010, based on the November 2009 submission (1973-2007 varying) [cited]. Available at www.seer.cancer.gov.
17. F. Berrino, R. De Angelis, M. Sant, S. Rosso, M. Bielska-Lasota, and J.W. Coebergh Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study Lancet Oncol 8 2007 773 783
18. J. Whitehead Fitting Cox's regression model to survival data using GLIM J R Stat Soc Ser C Appl Stat 29 1980 268 275
19. K.A. Cronin, and E.J. Feuer Cumulative cause-specific mortality for cancer patients in the presence of other causes: a crude analogue of relative survival Stat Med 19 2000 1729 1740
20. H.G. Welch, P.C. Albertsen, R.F. Nease, T.A. Bubolz, and J.H. Wasson Estimating treatment benefits for the elderly: the effect of competing risks Ann Intern Med 124 1996 577 584
21. Kolata G. Studies show prostate test saves few lives. New York Times. 2009 March 19.
22. Ablin R. The great prostate mistake. New York Times. 2010 March 9.
23. Woolston C. The debate over prostate cancer tests. Los Angeles Times. 2011 March 7.
24. H.G. Welch, and P.C. Albertsen Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005 J Natl Cancer Inst 101 2009 1325 1329
25. A. Richardson Screening and the number needed to treat J Med Screen 8 2001 125 127
26. A. Shteynshlyuger, and G.L. Andriole Cost-effectiveness of prostate specific antigen screening in the United States: extrapolating from the European study of screening for prostate cancer J Urol 185 2011 828 832
27. E.D. Crawford, R. Grubb 3rd, A. Black, G.L. Andriole Jr. , M.H. Chen, and G. Izmirlian Comorbidity and mortality results from a randomized prostate cancer screening trial J Clin Oncol 29 2011 355 361